Qie Y, Jia K, Huang S, Zhao J, et al. Disitamab Vedotin Plus Tislelizumab in Transurethrally Unresectable, ERBB2-Positive, Non-Muscle-Invasive Bladder Cancer: A Nonrandomized Clinical Trial. JAMA Oncol 2026 Oct 8. doi: 10.1001/jamaoncol.2026.3909.
PMID: 42848391